https://orcid.org/0000-0003-2433-2563
Abstract
Chemotherapy is a critical treatment modality for cancer patients, but multidrug resistance remains one of the major challenges in cancer therapy, creating an urgent need for the development of novel potent chemical entities. Azoles, particularly pyrazole, could interact with different biological targets and exhibit diverse biological properties including anticancer activity. Many clinically used anticancer agents own an azole moiety, demonstrating that azoles are privileged and pivotal templates in the discovery of novel anticancer chemotherapeutics. The present article is an attempt to highlight the recent advances in pyrazole–azole hybrids with anticancer potential and discuss the structure–activity relationships, covering articles published from 2018 to present, to facilitate the rational design of more effective anticancer candidates.
Author contributions
All authors contributed to the conception and organization of this review. S Zhang was responsible for collecting documents, writing the manuscript and organizing the structures of manuscript. Y Ye was responsible for collecting documents and revising the manuscript. Q Zhang and Y Luo were responsible for collecting documents and writing the manuscript. Z-C Wang was responsible for responses to reviewer questions and revising the manuscript. Y-Z Wu and X-P Zhang were responsible for collecting documents. C Yi was responsible for organizing, revising and editing the manuscript.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.